Is It Time to Sell MercadoLibre?
MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…
Buy
51
LFMD Quote, Financials, Valuation and Earnings
Last price:
$12.29
Seasonality move
:
21.49%
Day range:
$12.29 - $12.85
52-week range:
$3.99 - $13.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.31x
P/B ratio:
--
Volume:
1.9M
Avg. volume:
2.4M
1-year change:
67.99%
Market cap:
$574.9M
Revenue:
$212.5M
EPS (TTM):
-$0.34
Analysts' Opinion
-
Consensus RatingLifeMD has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $12.63, LifeMD has an estimated downside of -0.2% from its current price of $12.65.
-
Price Target UpsideAccording to analysts, the highest upside price target is $15.00 representing -100% upside increase from its current price of $12.65.
Fair Value
-
According to the consensus of 7 analysts, LifeMD has -0.2% downside to fair value with a price target of $12.63 per share.
LFMD vs. S&P 500
-
Over the past 5 trading days, LifeMD has overperformed the S&P 500 by 8.55% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
LifeMD does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LifeMD has grown year-over-year revenues for 26 quarters straight. In the most recent quarter LifeMD reported revenues of $65.7M.
Earnings Growth
-
LifeMD has grown year-over-year earnings for 0 quarters straight. In the most recent quarter LifeMD reported earnings per share of $0.01.
Enterprise value:
560.9M
EV / Invested capital:
31.10x
Price / LTM sales:
2.31x
EV / EBIT:
--
EV / Revenue:
2.40x
PEG ratio (5yr expected):
--
EV / Free cash flow:
177.16x
Price / Operating cash flow:
170.92x
Enterprise value / EBITDA:
214.17x
Gross Profit (TTM):
$205.9M
Return On Assets:
-15.6%
Net Income Margin (TTM):
-4.59%
Return On Equity:
--
Return On Invested Capital:
-66.95%
Operating Margin:
3.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $123.1M | $163.6M | $234M | $44.1M | $65.7M | |
| Gross Profit | $105.5M | $144.3M | $205.9M | $39.5M | $57.1M | |
| Operating Income | -$29.4M | -$17.8M | -$7.4M | -$6.2M | $2.5M | |
| EBITDA | -$25.1M | -$10.2M | $2.6M | -$4.1M | $5.2M | |
| Diluted EPS | -$1.26 | -$0.74 | -$0.34 | -$0.19 | $0.01 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.8M | $29.6M | $19.2M | $44.4M | $50M | |
| Total Assets | $18.7M | $50.3M | $33.9M | $61.5M | $73.6M | |
| Current Liabilities | $15.4M | $25.6M | $27M | $44.7M | $60.9M | |
| Total Liabilities | $15.8M | $33.9M | $41.2M | $60.2M | $74M | |
| Total Equity | $2.9M | $16.4M | -$7.4M | $1.3M | -$392.8K | |
| Total Debt | $674.3K | $63.4K | $15.2M | $18.1M | $18.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.5M | $16.6M | $15.4M | $5.2M | $3.1M | |
| Cash From Investing | -$8.3M | -$9.1M | -$12.2M | -$2.2M | -$2.9M | |
| Cash From Financing | $12.2M | $16.1M | -$3.9M | -$1M | -$812.6K | |
| Free Cash Flow | -$25.8M | $7.5M | $3.2M | $3M | $201K | |
LFMD
Sector
Market Cap
$574.9M
$33.6M
Price % of 52-Week High
95.47%
45.68%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
68%
-38.85%
Beta (5-Year)
2.423
0.633
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-28.95%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.91
200-day SMA
Buy
Level
$5.95
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$10.32
Relative Strength Index (RSI14)
Buy
Level
76.77
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-12.685
50-day SMA
Buy
Level
$7.63
MACD (12, 26)
Buy
Level
1.44
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9208)
Sell
CA Score
(Annual)
Level (-2.6654)
Buy
Beneish M-Score
(Annual)
Level (-4.378)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.3463)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Stock Forecast FAQ
In the current month, LFMD has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LFMD average analyst price target in the past 3 months is $12.63.
-
Where Will LifeMD Stock Be In 1 Year?
According to analysts, the consensus estimate is that LifeMD share price will drop to $12.63 per share over the next 12 months.
-
What Do Analysts Say About LifeMD?
Analysts are divided on their view about LifeMD share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LifeMD is a Sell and believe this share price will rise from its current level to $8.00.
-
What Is LifeMD's Price Target?
The price target for LifeMD over the next 1-year time period is forecast to be $12.63 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LFMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LifeMD is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LFMD?
You can purchase shares of LifeMD via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LifeMD shares.
-
What Is The LifeMD Share Price Today?
LifeMD was last trading at $12.29 per share. This represents the most recent stock quote for LifeMD. Yesterday, LifeMD closed at $12.65 per share.
-
How To Buy LifeMD Stock Online?
In order to purchase LifeMD stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Stock High Risk or High Reward?
EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…
Why Did Chase Coleman Buy TSM?
Billionaire Chase Coleman of Tiger Global Management has built a…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 48x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
52
CTRN alert for Jun 5
Citi Trends [CTRN] is up 2.77% over the past day.
Sell
44
RGC alert for Jun 4
Regencell Bioscience Holdings [RGC] is up 3.45% over the past day.
Buy
63
MLTX alert for Jun 4
MoonLake Immunotherapeutics [MLTX] is up 5.33% over the past day.
